WallStreetZenWallStreetZen

NASDAQ: SLS
Sellas Life Sciences Group Inc Stock

$1.14+0.05 (+4.59%)
Updated Jul 16, 2024
Why Price Moved
SLS Price
$1.14
Fair Value Price
$0.06
Market Cap
$65.84M
52 Week Low
$0.50
52 Week High
$1.90
P/E
-1.04x
P/B
6.8x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$35.81M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.52
Operating Cash Flow
-$30M
Beta
0.89
Next Earnings
Aug 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A

SLS Overview

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SLS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SLS ($1.14) is overvalued by 1,736.77% relative to our estimate of its Fair Value price of $0.06 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SLS ($1.14) is not significantly undervalued (1,736.77%) relative to our estimate of its Fair Value price of $0.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SLS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SLS due diligence checks available for Premium users.

Be the first to know about important SLS news, forecast changes, insider trades & much more!

SLS News

Valuation

SLS fair value

Fair Value of SLS stock based on Discounted Cash Flow (DCF)
Price
$1.14
Fair Value
$0.06
Overvalued by
1,736.77%
SLS ($1.14) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SLS ($1.14) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SLS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SLS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.04x
Industry
-18x
Market
31.71x

SLS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
6.8x
Industry
6.51x
SLS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SLS's financial health

Profit margin

Revenue
$0.0
Net Income
-$9.6M
Profit Margin
0%
SLS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$24.4M
Liabilities
$14.8M
Debt to equity
1.52
SLS's short-term assets ($21.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SLS's short-term assets ($21.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SLS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SLS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$10.8M
Investing
$0.0
Financing
$26.6M
SLS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SLS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SLS$65.84M+4.59%-1.04x6.80x
CSBR$66.07M-2.99%-6.75x-32.10x
HOOK$65.31M+11.49%-1.32x0.62x
ALRN$66.71M+3.69%-0.96x0.73x
GNTA$67.22M+2.50%-5.30x3.03x

Sellas Life Sciences Group Stock FAQ

What is Sellas Life Sciences Group's quote symbol?

(NASDAQ: SLS) Sellas Life Sciences Group trades on the NASDAQ under the ticker symbol SLS. Sellas Life Sciences Group stock quotes can also be displayed as NASDAQ: SLS.

If you're new to stock investing, here's how to buy Sellas Life Sciences Group stock.

What is the 52 week high and low for Sellas Life Sciences Group (NASDAQ: SLS)?

(NASDAQ: SLS) Sellas Life Sciences Group's 52-week high was $1.90, and its 52-week low was $0.50. It is currently -40% from its 52-week high and 128.46% from its 52-week low.

How much is Sellas Life Sciences Group stock worth today?

(NASDAQ: SLS) Sellas Life Sciences Group currently has 57,754,928 outstanding shares. With Sellas Life Sciences Group stock trading at $1.14 per share, the total value of Sellas Life Sciences Group stock (market capitalization) is $65.84M.

Sellas Life Sciences Group stock was originally listed at a price of $315,300.00 in Mar 12, 2008. If you had invested in Sellas Life Sciences Group stock at $315,300.00, your return over the last 16 years would have been -100%, for an annualized return of -54.3% (not including any dividends or dividend reinvestments).

How much is Sellas Life Sciences Group's stock price per share?

(NASDAQ: SLS) Sellas Life Sciences Group stock price per share is $1.14 today (as of Jul 16, 2024).

What is Sellas Life Sciences Group's Market Cap?

(NASDAQ: SLS) Sellas Life Sciences Group's market cap is $65.84M, as of Jul 17, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Sellas Life Sciences Group's market cap is calculated by multiplying SLS's current stock price of $1.14 by SLS's total outstanding shares of 57,754,928.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.